We are building Context Therapeutics to become a global company that will discover, develop and market groundbreaking cancer treatments to patients around the world, eliminating the fear that comes with a cancer diagnosis.
Know Your PR+ Status
If your cancer is PR+, then Apristor could be an option for you.
ONWARD are clinical research studies for breast, ovarian, and endometrial cancer patients who have metastatic disease.
Up to 70% of breast, ovarian, and endometrial cancers express progesterone receptor (PR). If your cancer is PR+, Apristor could be an option for you.